The cost-effectiveness of boceprevir for hepatitis C

References

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5(9):558-67
   PubMed Web of Science ®Google Scholar
• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010;14(1):1-21. vii
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55(2):245-64
   PubMed Web of Science ®Google Scholar
• Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res 2010;131:17-34
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9(4):331-8
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C Fact Sheet #164. Available from: www.who.int/mediacentre/factsheets/fs164/en/ [Last accessed 5 December 2013]
   Google Scholar
• Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009;9:34
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90(10):1562-9
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6):580-93
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705-16
   PubMed Web of Science ®Google Scholar
• Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009;13(3):429-39
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012;35(6):647-62
   PubMed Web of Science ®Google Scholar
• Liu S, Cipriano LE, Holodniy M, et al. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012;156(4):279-90
   PubMed Web of Science ®Google Scholar
• Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Oxford University Press; NY, USA: 2000
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; NY, USA: 2000
   Google Scholar
• Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics - an aid to better decision-making. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):34-9
   PubMed Web of Science ®Google Scholar
• Cammà C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012;56(3):850-60
   PubMed Web of Science ®Google Scholar
• Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13(1):190
   PubMed Web of Science ®Google Scholar
• Fonseca M, Garran V, Araujo GT. Cost effectiveness of boceprevir plus peginterferon alpha and ribavirin versus telaprevir plus peginterferon alfa and ribavirin in the treatment of chronic hepatitis C (CHC) in previously untreated genotype 1 patients. Value Health 2012;15(7):A328
   Web of Science ®Google Scholar
• Fonseca M, Tannus G, Parisi E. Cost effectiveness of boceprevir plus peginterferon alpha and ribavirin versus peginterferon alfa plus ribavirin in the treatment of chronic hepatitis C (CHC) in previously untreated genotype 1 patients. Value Health 2012;15(4):A139
   Google Scholar
• Jalundhwala YJ, Patel P, Nancy H, et al. Evaluating the cost-effectiveness of using boceprevir and telaprevir in the treatment of newly diagnosed Hepatitis C genotype 1 patients: a payer’s perspective. Pharmacotherapy 2012;32(10):E300-1
   Web of Science ®Google Scholar
• Blazquez-Perez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive Hepatitis C patients. Pharmacoeconomics 2013;31(10):919-31
   PubMed Web of Science ®Google Scholar
• Chan K, Lai MN, Groessl EJ, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol 2013;11(11):1503-10
   PubMed Web of Science ®Google Scholar
• Morais AD, Pereira ML. Cost per cure of telaprevir and boceprevir in treatment-naïve genotype 1 hepatitis C patients with F2 fibrosis in Brazil. Value Health 2013;16(7):A352
   Web of Science ®Google Scholar
• Ramachandran S, Mahabaleshwarkar R, Yang Y. Cost effectiveness analysis of addition of telaprevir or boceprevir to standard therapy versus standard therapy alone for the treatment of previously untreated chronic hepatitis-C virus genotype 1 infection. Value Health 2012;15(4):A242
   Web of Science ®Google Scholar
• Chhatwal J, Ferrante SA, Brass C, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013;16(6):973-86
   PubMed Web of Science ®Google Scholar
• Fonseca M, Tannus G, Parisi E. Cost effectiveness of the combination of boceprevir plus peginterferon alpha and ribavirin versus peginterferon alfa plus ribavirin in the retreatment of patients with chronic hepatitis C virus genotype 1 infection. Value Health 2012;15(4):A139
   Google Scholar
• Athanasakis K, Karampli E, Retsa MP, et al. Cost effectiveness analysis of boceprevir (BOC) added to pegifn/ribavirin (P/R) versus pegifn/ribavirin (current standard of care) for the treatment of patients with genotype 1 chronic hepatitis C in Greece. Value Health 2013;16(7):A352
   Web of Science ®Google Scholar
• Becker B, Chhatwal J, Ferrante S, et al. Cost-effectiveness of boceprevir-based treatment of chronic genotype 1 hepatitis C virus (HCV) infection from the perspective of the German Statutory Health Insurance (SHI). Value Health 2012;15(7):A392
   Web of Science ®Google Scholar
• Chhatwal J, Lundberg J, Ferrante S, et al. Cost-effectiveness of boceprevir in the treatment of chronic hepatitis C genotype 1 in Sweden. J Hepatol 2012;56:S386-7
   Google Scholar
• Ehlers L, Ferrante S, Kristensen MH, et al. Cost-effectiveness of boceprevir add-on treatment of hepatitis C virus genotype 1 patients in Denmark. Value Health 2013;16(7):A354
   Web of Science ®Google Scholar
• Elbasha EH, Chhatwal J, Ferrante SA, et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal. Appl Health Econ Health Policy 2013;11(1):65-78
   PubMedGoogle Scholar
• Ferrante S, Elbasha EH, Poynard T, Boyaval G. Boceprevir use in France: a markov model of disease progression and cost-effectiveness for chronic hepatitis C (Virus G1). Value Health 2013;16(7):A359
   Web of Science ®Google Scholar
• Humphreys SC, Elbasha EH, Ferrante SA, et al. Cost-effectiveness of boceprevir in combination with pegylated interferon alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C: submission to the National Institute for Health and Clinical Excellence (NICE). Value Health 2012;15(7):A328-9
   Web of Science ®Google Scholar
• La Torre G, Miele L, Mannocci A, et al. Organizational and economic issues related to the introduction of boceprevir in the treatment of patients with genotype 1 chronic hepatitis C in Italy. Value Health 2013;16(7):A494-5
   Web of Science ®Google Scholar
• Manova M, Savova A, Stoimenova A, Petrova G. Budget impact analysis of HCV therapy cost after boceprevir addition to standard therapeutic regime. Value Health 2012;15(7):A333
   Web of Science ®Google Scholar
• Mernagh P, Feng J, Del Cuore M. Cost-effectiveness of boceprevir therapy in adult patients with chronic hepatitis C (HCV) genotype 1. Value Health 2013;16(3):A94
   Web of Science ®Google Scholar
• Morais AD, Pereira ML. Cost per sustained virological response of telaprevir and boceprevir in the treatment of genotype 1 hepatitis C patients according to the previous treatment response and the Metavir groups in Brazil. Value Health 2012;15(7):A395
   Web of Science ®Google Scholar
• Nikoglou E, Humphreys S, El Khoury A, et al. The clinical efficacy and cost-effectiveness of boceprevir in combination with pegylated interferon-alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C patients: a within trial analysis from the perspective of the Scottish National Health Service (NHS). Value Health 2011;14(7):A274
   PubMed Web of Science ®Google Scholar
• Odhiambo R, Chhatwal J, Ferrante SA, et al. Economic evaluation of boceprevir for the treatment of patients with genotype 1 chronic hepatitis C virus infection in Hungary. Value Health 2012;15(7):A390
   Web of Science ®Google Scholar
• Vellopoulou K, Van Agthoven M, Van Der Kolk A, et al. The cost-utility of telaprevir in combination with peginterfeon alpha and ribavirin (PR) as compared to the combination boceprevir with PR and to PR alone in the management of chronic hepatitis C in the Netherlands. Value Health 2012;15(7):A396
   Web of Science ®Google Scholar
• Yfantopoulos J, Paparouni K, D’Angelo ER. A cost-effectiveness analysis of telaprevir versus boceprevir in the treatment of hepatitis C: a Greek national health system perspective. Value Health 2012;15(7):A394
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Third National Health and Nutrition Examination Survey (NHNES) III. Available from: www.cdc.gov/nchs/nhanes/nh3data.htm [Last accessed 5 December 2013]
   Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290(2):228-37
   PubMed Web of Science ®Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52(5):652-7
   PubMed Web of Science ®Google Scholar
• Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40(5):823-30
   PubMed Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55(9):1332-8
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48(2):418-31
   PubMed Web of Science ®Google Scholar
• Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 2005;365(9454):176-86
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) + PR: the PROVIDE study interim results. J Hepatol 2012;56(Suppl 2):S6
   Web of Science ®Google Scholar
• Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011;52(7):889-900
   PubMed Web of Science ®Google Scholar
• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276(14):1172-7
   PubMed Web of Science ®Google Scholar
• Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008;167(6):743-50
   PubMed Web of Science ®Google Scholar
• Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010;59(8):1135-40
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6(3):217-27
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15(7):677-87
   PubMed Web of Science ®Google Scholar
• Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ 2011;342:d1766
   PubMed Web of Science ®Google Scholar
• Briggs A. Transportability of comparative effectiveness and cost-effectiveness between countries. Value Health 2010;13(Suppl 1):S22-5
   Google Scholar
• O’Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care 1997;3(Suppl 5):S33-9
   Google Scholar
• Diels J, Cure S, Gavart S. The comparative efficacy of telaprevir versus boceprevir in treatment-naive and treatment-experienced patients with genotype 1 chronic hepatitis. Value Health 2011;14(7):A266
   Web of Science ®Google Scholar
• Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147
   PubMed Web of Science ®Google Scholar
• McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008;28(4):582-92
   PubMed Web of Science ®Google Scholar
• Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005;100(3):643-51
   PubMed Web of Science ®Google Scholar
• Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009;360(8):816-23
   PubMed Web of Science ®Google Scholar
• Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol 2011;7(3):154-62
   PubMedGoogle Scholar
• American Association for the study of liver diseases and the infectious diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: www.hcvguidelines.org/ [Last accessed 12 February 2014]
   Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. J Hepatol 2013;59(3):434-41
   PubMed Web of Science ®Google Scholar